COBRA PzF

DEVICE3 trials

Sponsors

CeloNova BioSciences, Inc.

Conditions

Angina, StableAngina, UnstableAnticoagulantsCoronary Artery DiseaseStable Angina

Unknown Phase

COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT

CompletedNCT01925794

CeloNova BioSciences, Inc.Coronary Artery Disease

Start: 2013-08-21End: 2020-03-02Updated: 2021-12-22

COBRA SHIELD OCT Study

TerminatedNCT02224235

CeloNova BioSciences, Inc.Stable Angina

Start: 2014-06-30End: 2015-06-30Updated: 2020-10-06

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

CeloNova BioSciences, Inc.Angina, Stable, Angina, Unstable, Anticoagulants

Start: 2016-02-05End: 2021-11-30Updated: 2020-10-26

Related Papers

Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial

Circulation Cardiovascular Interventions2024-10-015 citations

Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE).

2021-01-2211 citations